Bays HE, Kulkarni A, German C, Satish P, Iluyomade A, Dudum R, et al. Ten things to know about ten cardiovascular disease risk factors – 2022. Am J Prev Cardiol. 2022;10:100342.
Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313–8.
Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176–80.
Carbayo Herencia JA, Simarro Rueda M, Palazon Bru A, Molina Escribano F, Ponce Garcia I, Artigao Rodenas LM, et al. Todos en nombre del Grupo de Enfermedades Vasculares de Albacete (GEVA). Evaluation of non-HDL cholesterol as a predictor of non-fatal cardiovascular events in a prospective population cohort. Clin Investig Arterioscler. 2018;30:64–71.
Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl. 2003;84:S117–20.
Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischemic heart disease: principal results oft he Northwick Park heart study. Lancet. 1986;2:533–7.
Baker IA, Eastham R, Elwood PC, Etherington M, O’Brien JR, Sweetnam PM. Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years. The Speedwell. Study Br Heart J. 1982;47:490–4.
Folsom AR, Conlan MG, Davis CED, Wu KK. For the atherosclerosis in communities (ARIC) study investigators. Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Ann Epidemiol. 1992;2:481–94.
Maseri A, Fuster V. Is there a vulnerable plaque? Circulation. 2003;107:2068–71.
Song B, Shu Y, Xu YN, Fu P. Plasma fibrinogen level and risk of coronary heart disease among Chinese population: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:13195–202.
Lowe G, Rumley A. The relevance of coagulation in cardiovascular disease: what do the biomarkers tell us? Thromb Haemost. 2014;112:860–7.
El-Hazmi MA. Hematological risk factors for coronary heart disease. Med Princ Pract. 2002;11(Suppl 2):56–62.
Georgieva AM, Cate HAT, Keulen ETP, van Oerle R, Govers-Riemslag JWP, Hamulyak K, et al. Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis. 2004;175:345–51.
Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97:785–97.
Wada H, Mori Y, Kaneko T, Wakita Y, Minamikawa K, Ohiwa M, et al. Hypercoagulable state in patients with hypercholesteriolemia: effects of pravastin. Clin Ther. 1992;14:829–34.
Poredos P, Jezovnik MK. Dyslipidemia, statins, and venous thromboembolism. Semin Thromb Hemost. 2011;37:897–902 Review.
Löwel H, Döring A, Schneider A, Heier M, Thorand B, Meisinger C, et al. The MONICA Augsburg surveys – basis for prospective cohort studies. Gesundheitswesen. 2005;67(Suppl 1):S13–8.
Meisinger C, Thorand B, Schneider A, Stieber J, Döring A, Löwel H. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med. 2002;162:82–9.
Meisinger C, Löwel H, Thorand B, Döring A. Leisure time physical activity and the risk of type 2 diabetes in men and women from the general population. The MONICA/KORA Augsburg Cohort Study. Diabetologia. 2005;48:27–34.
Meisinger C, Döring A, Thorand B, Löwel H. Association of cigarette smoking and tar and nicotine intake with the development of type 2 diabetes mellitus in men and women from the general population: the MONICA/KORA Augsburg cohort study. Diabetologia. 2006;49:1770–6.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use oft he preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
Hansen JB, Grimsgaard S, Huseby N, Sandset PM, Bonaa KH. Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men. Thromb Res. 2001;102:3–13.
Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the atherosclerosis risk in communities (ARIC) study. Thromb Haemost. 1993;70:762–7.
Koscielniak B, Wypasek E, Undas A. Determinants of elevated levels of natural anticoagulants in healthy subjects. Adv Clin Exp Med. 2015;24:791–800.
Trigg DE, Wood MG, Kouides PA, Kadir RA. Hormonal influences on hemostasis in women. Semin Thromb Hemost. 2011;37:077–86.
High KA. Antithrombin III, protein C, and protein S. Naturally occurring anticoagulant proteins. Arch Pathol Lab Med. 1988;112:28–36.
Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191–205.
Kario K, Matsuo T. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. Atherosclerosis. 1993;103:131–8.
Kostka B, Para J, Drygas W, Kostka T. Antithrombin III activity in the elderly – association with cardiovascular disease risk factors. Przegl Lek. 2005;62(Suppl 3):35–8.
Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors. The Scottish heart health study. J Clin Epidemiol. 1990;43:913–9.
Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost. 1985;54:721.
Moller L, Kristensen TS. Plasma fibrinogen and ischemic heart disease risk factors. Arterioscler Thromb. 1991;11:344.
Korsan-Bengtsen K, Wilhelmsen L, Tibblin G. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. II. Relations of the variables to “risk factors” for myocardial infarction. Thromb Diathes Haemorrh. 1972;28:99.
Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. Thr Framingham Study. JAMA. 1987;258:1183.
Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J. 1979;1:153.
Bonithon-Kopp C, Scarabin PY, Bara L, Castanier N, Jacqueson A, Roger M. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis. 1988;71:71.
Lew J, Sanghavi M, Ayers CR, McGuire DK, Omland T, Atzler D, et al. Sex-based differences in cardiometabolic biomarkers. Circulation. 2017;135:544–55.
Chan P, Tomlinsoin B, Tsai CW, Pan WH, Lee YS. Thrombophilia in patients with hypercholesterolemia. Metabolism. 1996;45:966–99.
Kim JA, Kim JE, Song SH, Kim HK. Influence of blood lipids on global coagulation test results. Ann Lab Med. 2015;35:15–21.
Chan P, Huang TY, Shieh SM, Lin TS, Tsai CW. Thrombophilia in patients with hypertriglyceridemia. J Thromb Thrombolysis. 1997;4:425–9.
Kowaka T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, et al. Tissue factor pathway inhibitor activity in human plasma. Arterioscler Thromb Vasc Biol. 1995;15:504–10.
Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitorydomains. J Biol Chem. 1988;263:6001–4.
Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood. 1987;69:645–51.
Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 1994;14:223–9.
Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 1991;2:425–33.